Navigation Links
Seaside publishes research supporting disease-modifying potential of STX209 for fragile X syndrome
Date:9/19/2012

CAMBRIDGE, Mass., (Embargoed until September 19, 2012, 2:00 PM US Eastern Time) Seaside Therapeutics today announced the publication of two papers in Science Translational Medicine, supporting its lead candidate, STX209 (arbaclofen), for the treatment of fragile X syndrome (FXS). The works presented highlight STX209 as a potential disease-modifying drug in preclinical studies, with improvement in social function in a clinical trial of patients with FXS.

"In preclinical results, we demonstrate that STX209 treatment corrects core aspects of FXS pathophysiology in the fragile X mouse model, leading us to conclude that STX209 is a disease-modifying drug with the potential to significantly improve the lives of patients with fragile X," said Randall Carpenter, MD, President and Chief Executive Officer of Seaside Therapeutics. "In fact, in our Phase 2 clinical trial, we observed statistically significant improvements in social avoidance, a core symptom of fragile X syndrome that is characterized by behaviors such as preference to be alone and being withdrawn or isolated. Social avoidance is also a core symptom of autism spectrum disorders, suggesting STX209 could have a positive effect in this larger patient population. Together, these results support our continued development of STX209, which is currently enrolling patients in a Phase 3 study in fragile X syndrome and recently completed enrollment in a Phase 2b study in autism spectrum disorders."

"There are currently no FDA approved therapeutics that address the core symptoms of fragile X syndrome, leaving patients and their caregivers with limited treatment options," said Elizabeth Berry-Kravis, MD, PhD, Professor of Pediatrics, Neurology, and Biochemistry at Rush University Medical Center in Chicago, and the lead author of the paper on the Phase 2 study results. "We are very excited about the clinically meaningful improvements in social impairment observed to date in patients receiving
'/>"/>

Contact: Kari Watson
kwatson@macbiocom.com
781-235-3060
MacDougall Biomedical Communications, Inc.
Source:Eurekalert

Page: 1 2 3 4

Related biology technology :

1. Receptos Co-Publishes Highest Resolution G-Protein Coupled Receptor Structure to Date in Science
2. Nonprofit Consortium Publishes Review of Skullcap Adulteration
3. Nucleic Acids Research Journal Publishes Sapphire Energy Peer-Reviewed Research Paper on a Chloroplast Genome From Green Algae
4. American Botanical Council Publishes a History of Adulteration
5. Stanford faculty awarded $2.2 million for innovative energy research
6. Electronics without current: Finnish team to research the future of nanoelectronics
7. Elsevier Offers Entire Collection of Journals and Books to Innovators in Developing Countries Through the Access to Research for Development and Innovation (ARDI) Program
8. Metabolic engineer synthesizes key breast milk ingredient, makes research possible
9. Penn researchers make first all-optical nanowire switch
10. Palatin Technologies Provides Update Regarding Its Obesity Research/Development Collaboration with AstraZeneca
11. All Market Research New Report @ Polyvinyl Chloride (PVC) Global Market to 2020 - Growth from Asia-Pacific Construction, Packaging and Electrical Sectors Continues to Drive Demand
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... Brighton, Illinois (PRWEB) February 27, 2015 ... Matt Sims, General Manager of State Line Farms, received ... Award recognizes a producer, under the age of 35, ... , "It is an honor to win the Tomorrow's ... to discovering who won the Top Producer Award and ...
(Date:2/26/2015)... , Feb. 26, 2015 S&P Capital ... Factual Stock Report coverage on MabVax Therapeutics Holdings Inc ... is a clinical stage biotechnology company focused on the ... medical needs in the treatment of cancer. MabVax has ... on the protective immune responses generated by patients who ...
(Date:2/26/2015)... Feb. 26, 2015   Synageva BioPharma Corp. ... company developing therapeutic products for rare disorders, today ... 2015 goals, other key objectives, and financial guidance.  ... today at 4:30 p.m. EST to review the ... To participate in today,s call by telephone, please ...
(Date:2/26/2015)... Angeles, CA (PRWEB) February 26, 2015 ... an online demonstration to support life extension technologies and ... 8pm UTC, Universal Coordinated Time, on March 21st 2015, ... the world. , Eric Schulke, Founder of MILE, ... must act with urgency. The Movement for Indefinite Life ...
Breaking Biology Technology:Matt Sims Receives the 2015 Tomorrow’s Top Producer Horizon Award 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 5Synageva BioPharma Reports 2014 Full Year Financial Results 2Synageva BioPharma Reports 2014 Full Year Financial Results 3Synageva BioPharma Reports 2014 Full Year Financial Results 4Synageva BioPharma Reports 2014 Full Year Financial Results 5Synageva BioPharma Reports 2014 Full Year Financial Results 6Synageva BioPharma Reports 2014 Full Year Financial Results 7Synageva BioPharma Reports 2014 Full Year Financial Results 8Synageva BioPharma Reports 2014 Full Year Financial Results 9Indefinite Life Extension Activists Organize Online Demonstration 2Indefinite Life Extension Activists Organize Online Demonstration 3
... Intercell,s IXIARO, the first licensed vaccine against Japanese ... -- This final decision follows the positive opinion ... in December 2008VIENNA, April 2 Intercell AG ... to prevent Japanese Encephalitis, IXIARO(R), has been approved ...
... for detection of methicillin-resistant Staphylococcus aureus for better patient ... its new LightCycler(R) test for the detection of methicillin-resistant ... the CE Mark, allowing it to be sold for ... Advanced Test is a qualitative in vitro ...
... - Conference Call Scheduled for Today at 5:00 p.m. ... Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS ) ... fiscal year ended December 31, 2008.Total revenue for the ... a net loss of $37.2 million. As of December ...
Cached Biology Technology:Intercell Announces European Approval of New Vaccine, IXIARO(R), to Prevent Japanese Encephalitis 2Intercell Announces European Approval of New Vaccine, IXIARO(R), to Prevent Japanese Encephalitis 3Intercell Announces European Approval of New Vaccine, IXIARO(R), to Prevent Japanese Encephalitis 4Roche to Introduce New LightCycler(R) MRSA Advanced Test in the EU 2Roche to Introduce New LightCycler(R) MRSA Advanced Test in the EU 3Roche to Introduce New LightCycler(R) MRSA Advanced Test in the EU 4Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results 2Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results 3Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results 4Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results 5Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results 6Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results 7Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results 8Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results 9Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results 10Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results 11
(Date:2/5/2015)... , Feb. 3, 2015 Despite a ... from industries such as consumer electronics, automotive, storage ... surface mount technology (SMT) screen printers. Innovations in ... control will push the adoption curve up. Meanwhile, ... steady as glue dispensers are indispensable in the ...
(Date:1/22/2015)... Jan. 13, 2015  Today, FreeWavz ( www.FreeWavz.com ), ... crowdfunding campaign on Fundable, https://www.fundable.com/freewavz . FreeWavz ... production capacity to meet customer demand. ... http://photos.prnewswire.com/prnh/20150113/168790 Invented by ...
(Date:1/22/2015)... NXT-ID, Inc. (NASDAQ: NXTD and NXTDW) a biometric authentication ... success of the Wocket™ smart wallet at CES 2015 in ... as one of the "11 Hot Products at CES" in a review ... So Far" by Newseveryday.com and "The top 10 gadgets from CES 2015" ...
Breaking Biology News(10 mins):End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 2End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 3FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3
... PORTLAND, Ore. -- Pediatric neuroscientists at Oregon Health & ... use high magnetic field strength MRI to reveal tiny ... using standard MRI. Early, accurate identification of ... delays in therapy and enable physicians to inform families ...
... Steven B. Abramson, MD, senior vice president and vice ... Departments of Medicine and Pathology at NYU Langone Medical ... American College of Rheumatology (ACR) & Association of Rheumatology ... Chicago. The Distinguished Basic Investigator Award is a ...
... the RIKEN Brain Science Institute (BSI) have discovered a ... proteins from the cell. Their findings indicate that the ... the phosphorylation of a protein called p62, opening the ... as Huntington,s disease and Alzheimer,s disease. One of ...
Cached Biology News:First use of high-field MRI in developing brain reveals previously undetectable injuries 2Steven B. Abramson, MD, receives distinguished Basic Investigator Award at ACR 2011 2
Caliper offers a wide array of standard LabChip products designed to be used in combination with our AMS 90 and LabChip 3000 microfluidic platforms....
...
Experion StdSens chips are the microfluidic chips used to perform standard-sensitivity RNA analysis (nanogram levels) with the Experion automated electrophoresis system. Each chip has the capacity to...
Experion HighSens chips are the microfluidic chips used to perform high-sensitivity RNA analysis (picogram levels) with the Experion automated electrophoresis system. Each chip has the capacity to ru...
Biology Products: